CIBC Asset Management Inc Boosts Stake in Natera, Inc. (NASDAQ:NTRA)

CIBC Asset Management Inc increased its position in Natera, Inc. (NASDAQ:NTRA) by 5.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,663 shares of the medical research company’s stock after buying an additional 186 shares during the period. CIBC Asset Management Inc’s holdings in Natera were worth $580,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. State of New Jersey Common Pension Fund D lifted its position in shares of Natera by 0.8% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 43,584 shares of the medical research company’s stock worth $6,899,000 after buying an additional 343 shares in the last quarter. Capital Performance Advisors LLP raised its position in Natera by 66.8% during the fourth quarter. Capital Performance Advisors LLP now owns 1,655 shares of the medical research company’s stock valued at $262,000 after purchasing an additional 663 shares during the period. Principal Securities Inc. raised its position in Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 59 shares during the period. Montag A & Associates Inc. raised its position in Natera by 190.2% during the fourth quarter. Montag A & Associates Inc. now owns 505 shares of the medical research company’s stock valued at $80,000 after purchasing an additional 331 shares during the period. Finally, Roxbury Financial LLC purchased a new stake in Natera during the fourth quarter valued at approximately $126,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Stock Down 3.5 %

Shares of NASDAQ:NTRA opened at $162.31 on Friday. Natera, Inc. has a 52-week low of $69.74 and a 52-week high of $183.00. The stock has a market cap of $21.43 billion, a P/E ratio of -92.22 and a beta of 1.66. The business’s 50 day moving average is $167.98 and its 200 day moving average is $145.54. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on NTRA shares. Morgan Stanley upped their price objective on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Guggenheim upped their price objective on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 17th. Barclays started coverage on Natera in a research report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 price objective on the stock. Piper Sandler upped their price objective on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, November 18th. Finally, TD Cowen increased their price target on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $170.94.

Insider Buying and Selling

In other Natera news, Director Roelof Botha sold 87,473 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $169.12, for a total transaction of $14,793,433.76. Following the sale, the director now owns 1,224,787 shares of the company’s stock, valued at approximately $207,135,977.44. This trade represents a 6.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 78,553 shares of the stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the sale, the chief executive officer now directly owns 267,629 shares in the company, valued at $44,150,756.13. This trade represents a 22.69 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 295,772 shares of company stock valued at $49,741,699 over the last quarter. 7.60% of the stock is owned by corporate insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.